Post-approval studies (Phase 4)UnknownNCT01665417
What this trial is testing
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
Who this might be right for
EGFR Positive Non-small Cell Lung CancerAdenocarcinoma
Betta Pharmaceuticals Co., Ltd. 100